BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30098109)

  • 1. TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway.
    Xiong D; Jin C; Ye X; Qiu B; Jianjun X; Zhu S; Xiang L; Wu H; Yongbing W
    Cancer Sci; 2018 Oct; 109(10):3080-3092. PubMed ID: 30098109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4.
    Wei CY; Wang L; Zhu MX; Deng XY; Wang DH; Zhang SM; Ying JH; Yuan X; Wang Q; Xuan TF; He AQ; Qi FZ; Gu JY
    J Exp Clin Cancer Res; 2019 Mar; 38(1):137. PubMed ID: 30922374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of long non-coding RNA DUXAP8 suppresses proliferation, metastasis and EMT by modulating miR-498 through TRIM44-mediated AKT/mTOR pathway in non-small-cell lung cancer.
    Ji X; Tao R; Sun LY; Xu XL; Ling W
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3152-3165. PubMed ID: 32271433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway.
    Xing Y; Meng Q; Chen X; Zhao Y; Liu W; Hu J; Xue F; Wang X; Cai L
    Oncotarget; 2016 May; 7(21):30479-91. PubMed ID: 27058415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling.
    Peng R; Zhang PF; Zhang C; Huang XY; Ding YB; Deng B; Bai DS; Xu YP
    Cancer Med; 2018 Mar; 7(3):796-808. PubMed ID: 29446253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy.
    Ong CA; Shannon NB; Ross-Innes CS; O'Donovan M; Rueda OM; Hu DE; Kettunen MI; Walker CE; Noorani A; Hardwick RH; Caldas C; Brindle K; Fitzgerald RC
    J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of TRIM44 Inhibits the Proliferation and Invasion in Prostate Cancer Cells.
    Tan Y; Yao H; Hu J; Liu L
    Oncol Res; 2017 Sep; 25(8):1253-1259. PubMed ID: 28160462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen promotes malignant biological tumor behavior involving epithelial-mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma.
    Zhang F; Wang Y; Sun P; Wang ZQ; Wang DS; Zhang DS; Wang FH; Fu JH; Xu RH; Li YH
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2413-2424. PubMed ID: 28801734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.
    Kawabata H; Azuma K; Ikeda K; Sugitani I; Kinowaki K; Fujii T; Osaki A; Saeki T; Horie-Inoue K; Inoue S
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor.
    Yamada Y; Takayama KI; Fujimura T; Ashikari D; Obinata D; Takahashi S; Ikeda K; Kakutani S; Urano T; Fukuhara H; Homma Y; Inoue S
    Cancer Sci; 2017 Jan; 108(1):32-41. PubMed ID: 27754579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression.
    Wang L; Zhang Z; Yu X; Li Q; Wang Q; Chang A; Huang X; Han X; Song Y; Hu J; Pang L; Hou J; Li F
    Cancer Lett; 2020 Jan; 468():14-26. PubMed ID: 31600529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIM-3 promotes the metastasis of esophageal squamous cell carcinoma by targeting epithelial-mesenchymal transition via the Akt/GSK-3β/Snail signaling pathway.
    Shan B; Man H; Liu J; Wang L; Zhu T; Ma M; Xv Z; Chen X; Yang X; Li P
    Oncol Rep; 2016 Sep; 36(3):1551-61. PubMed ID: 27430162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma.
    Yamada Y; Kimura N; Takayama KI; Sato Y; Suzuki T; Azuma K; Fujimura T; Ikeda K; Kume H; Inoue S
    Cancer Sci; 2020 Mar; 111(3):881-890. PubMed ID: 31883420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between tripartite motif-containing protein 44 protein expression and the prognosis of postoperative patients exhibiting skin squamous cell carcinoma.
    Wu J; Guo NZ; Cui LL; Wang W; Xiong CQ; Zhang XY
    Medicine (Baltimore); 2018 Nov; 97(44):e13021. PubMed ID: 30383661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.
    Zhou X; Yang Y; Ma P; Wang N; Yang D; Tu Q; Sun B; Xiang T; Zhao X; Hou Z; Fang X
    J Neurooncol; 2019 Nov; 145(2):211-222. PubMed ID: 31605296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K/AKT/mTOR signaling pathway.
    Zhang Y; Chen W; Wang H; Pan T; Zhang Y; Li C
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1209-1218. PubMed ID: 31529206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM14 promotes the migration and invasion of gastric cancer by regulating epithelial‑to‑mesenchymal transition via activation of AKT signaling regulated by miR‑195‑5p.
    Wang F; Ruan L; Yang J; Zhao Q; Wei W
    Oncol Rep; 2018 Dec; 40(6):3273-3284. PubMed ID: 30272351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
    Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
    Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.